Related Experiment Videos
[Clinical studies of bestatin on genitourinary cancer]
Abstract:
Bestatin was administered to 20 patients with urogenital tumors. The therapeutic results showed 12 surviving patients and 8 dead patients (including 7 due to cancer and 1 due to a cerebrovascular disorder). One patient has survived for 5 years since bestatin treatment of pulmonary metastasis of renal cancer, and one other patient achieved 5-year survival in spite of systemic metastases of testicular tumor. It is noteworthy that in earlier times these patients could have been expected to experience sudden relapse and aggravation, instead of the long-term survival recorded in this bestatin trial. Studies were conducted on the immunological parameters of the patients before and after the use of bestatin, and it was found that these parameters showed improvement as a result of the treatment. Even though bestatin was ingested for long periods of time by these patients, there was almost no development of adverse reactions to the treatment.
Insights
Bestatin treatment demonstrated promising survival rates in patients with urogenital tumors, showing improved immunological parameters and minimal adverse effects in this study.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Context:
- Urogenital tumors represent a significant health concern with limited therapeutic options.
- Assessing novel therapeutic agents for improving patient survival and quality of life is crucial.
Purpose:
- To evaluate the efficacy and safety of bestatin in patients diagnosed with urogenital tumors.
- To investigate the impact of bestatin on immunological parameters in cancer patients.
Summary:
- Bestatin was administered to 20 patients with urogenital tumors, resulting in 12 survivors and 8 deaths.
- Notably, long-term survival was observed in patients with advanced metastatic disease, including renal and testicular cancers.
- Immunological parameters improved post-treatment, and bestatin was well-tolerated with minimal adverse reactions during prolonged use.
Impact:
- Bestatin shows potential as a therapeutic agent for urogenital tumors, offering improved survival outcomes.
- The observed immunomodulatory effects suggest a potential mechanism for its anti-cancer activity.
- This study highlights the favorable safety profile of bestatin, even with extended administration.